Elena Cojocaru

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5854266/publications.pdf

Version: 2024-02-01

1478280 1281743 11 444 11 6 citations h-index g-index papers 11 11 11 707 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	KIT-Associated Familial GIST Syndrome: Response to Tyrosine Kinase Inhibitors and Implications for Risk Management. Oncologist, 2022, 27, 615-620.	1.9	6
2	Clinical management and outcomes of primary ovarian leiomyosarcoma – Experience from a sarcoma specialist unit. Gynecologic Oncology Reports, 2021, 36, 100737.	0.3	9
3	Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. Medical Oncology, 2020, 37, 13.	1.2	18
4	Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. JCO Global Oncology, 2020, 6, 1046-1051.	0.8	89
5	Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer Research, 2020, 40, 7003-7007.	0.5	3
6	Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. Clinical Sarcoma Research, 2020, 10, 9.	2.3	5
7	Exploiting the folate receptor α in oncology. Nature Reviews Clinical Oncology, 2020, 17, 349-359.	12.5	262
8	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. Oncologist, 2020, 25, e1777-e1784.	1.9	27
9	Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?. Current Molecular Biology Reports, 2020, 6, 1-9.	0.8	20
10	Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services. European Journal of Cancer, 2019, 114, 97-106.	1.3	4
11	Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. Journal of Immunotherapy and Precision Oncology, 2019, 2, 23-35.	0.6	1